Bristol claims victory in crucial immunotherapy trial, but results raise some questions

Ebony Scott
February 11, 2018

The company's net earnings from the same period of the year prior was $894 million.

Bristol-Myers Squibb Company (BMY) shares are down -1.2% for the week and that has got investors and traders sitting up and taking note.

Summit Financial Wealth Advisors LLC reduced its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 28.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. Analysts were expecting revenue of $5.35 billion. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the Zacks' consensus estimate of $0.67 by $0.01.

Xylem Inc. (NYSE:XYL)'s earnings per share has been growing at a -0.8 percent rate over the past 5 year when average revenue increase was noted as -0.2 percent. The cost of products sold was $1.67 billion, up 21%. Janus Henderson Group PLC grew its stake in Bristol-Myers Squibb by 2,990.5% in the 2nd quarter.

Eliquis sales jumped 46% for the year to $4.87 billion, with $2.88 billion of the haul coming from the U.S. The results come as BMS battles neck and neck with Johnson & Johnson and Bayer for market dominance with their new anticoagulants.

For the year, the company reported profit of $1.01 billion, or 61 cents per share. However, this loss was due to a one-time $3 billion transitional impact from US tax reform. Xact Kapitalforvaltning AB grew its holdings in shares of Bristol-Myers Squibb by 3.4% in the 2nd quarter.

Bristol-Myers Squibb Company (NYSE:BMY) closed February 02 at $63.48, down -3.96% or $2.62 from its record high price of $66.1. Analysts' estimates typically exclude special items. BMS stated that the combo of the two immuno-oncology (I-O) drugs met its co-primary endpoint of progression-free survival (PFS) in patients with high TMB, regardless of PD-L1 expression. In addition to these important findings, a second part of the trial, which is assessing overall survival with the Opdivo plus Yervoy combination, is continuing as planned. TMB is being evaluated using Foundation Medicine's (NASDAQ:FMI) FoundationOne CDx assay.

Exxon Mobil: What To Do Now
The shares price has positioned at -5.81% over the past quarter while it has directed -2.26% during past six months. Aviance Capital Management Llc decreased Exxon Mobil Corp ( XOM ) stake by 80.45% reported in 2017Q3 SEC filing.

United States spies, seeking to retrieve cyberweapons, paid Russian peddling dirt on Trump
Officials told the man to either leave Western Europe or face criminal charges. NSA officials were not available out of regular business hours for comment.

Officer in Canada prime minister motorcade hurt
The location of the speech carried symbolic weight, alluding to the longstanding trade relationship between the US and Canada. In 1988, Reagan and then-Prime Minister Brian Mulroney signed the first free trade agreement - a precursor to the Nafta .

Bristol-Myers Squibb Company (NYSE:BMY) closed its last session at $63.48.

Research and development expenses increased 37% to $1.9 billion in the quarter primarily due to license and asset acquisition charges of $377 million in the fourth quarter of 2017. The institutional investor held 15,566 shares of the agricultural chemicals company at the end of 2017Q3, valued at $1.87 million, down from 35,666 at the end of the previous reported quarter.

That's good news for shareholders for a couple of reasons. The company continues to be well positioned to keep those dividends flowing.

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. Revenue from the company's Hepatitis C franchise fell 74% to $59 million and revenue from the company's Reyataz franchise, which treats HIV, fell 31% to $143 million. This showed a surprise of -2.6% in the last quarter earnings. Bristol-Myers Squibb Company (NYSE:BMY) is 7.26% above its 200-day moving average, providing a measure of resistance for long positions.

In November, at the Society for Immunotherapy of Cancer Annual Meeting, the company announced results from studies evaluating BMS-986205, an investigational IDO1 inhibitor, and cabiralizumab (FPA008), an investigational anti-CSF-1 receptor antibody, in combination with Opdivo. Those results bode well for sustained growth for Opdivo, which is on track to become the No. 2 best-selling cancer drug in the world over the next few years. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned "Underweight" rating by Piper Jaffray on Monday, August 24.

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Parkside Fincl Bank And Tru reported 0.47% in Bristol-Myers Squibb Company (NYSE:BMY). Evaluating stocks to buy and sell can be a tricky business, even with all of the data available at your fingertips. The Motley Fool has a disclosure policy. The Motley Fool has no position in any of the stocks mentioned.

Other reports by GizPress

Discuss This Article